Evidence map›Paper›PMID 33175216›Full record

ArticleVirchows Archiv : an international journal of pathology2021

The impact of pre-analytical parameters on class II biomarkers by immunohistochemistry: concordance across four tissue processing protocols.

Bin Xu, Samira Alminawi, Patrice Boulianne, Yan Ming Shang, Michelle R Downes, Elzbieta Slodkowska

Abstract readComparative Study
PubMed Publisher
In one paragraph

Article in Virchows Archiv : an international journal of pathology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.2field-weighted citation impact, top 56% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 4 citations in OpenAlex.

  1. Review
  2. Immunohistochemistry for PTEN testing in HR +/HER2- metastatic breast cancer.Virchows Archiv : an international journal of pathology · 2025
    Review
  3. Impact of formalin fixation on mismatch repair protein evaluation by immunohistochemistry.Virchows Archiv : an international journal of pathology · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 2 countries.

Bin XuDepartment of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Samira AlminawiDivision of Anatomic Pathology, Laboratory Medicine & Molecular Diagnostics, Sunnybrook Health Sciences Centre and University of Toronto, Toronto, ON, Canada.
Patrice BoulianneDivision of Anatomic Pathology, Laboratory Medicine & Molecular Diagnostics, Sunnybrook Health Sciences Centre and University of Toronto, Toronto, ON, Canada.
Yan Ming ShangDivision of Anatomic Pathology, Laboratory Medicine & Molecular Diagnostics, Sunnybrook Health Sciences Centre and University of Toronto, Toronto, ON, Canada.
Michelle R DownesDivision of Anatomic Pathology, Laboratory Medicine & Molecular Diagnostics, Sunnybrook Health Sciences Centre and University of Toronto, Toronto, ON, Canada.
Elzbieta SlodkowskaDivision of Anatomic Pathology, Laboratory Medicine & Molecular Diagnostics, Sunnybrook Health Sciences Centre and University of Toronto, Toronto, ON, Canada. elzbieta.slodkowska@sunnybrook.ca.
University of Toronto · CAHealth Sciences Centre · CAMemorial Sloan Kettering Cancer Center · US

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Nicholas D Socci · 1985 to 2026
$347.4M
NCI NIH HHS P30CA008748
6 · The paper itself

Abstract

In the modern era of precision medicine, a number of class II immunohistochemistry (IHC) biomarkers are routinely tested in pathologic laboratories to select cancer patients who may be candidates for hormonal, targeted, and immune therapies. Pre-analytical factors, including tissue processing, are critical components of biomarker testing and require validation to ensure reliable results. In this study, we aimed to study the impact of tissue processing on biomarkers (including ER, PR, HER2, mismatch repair (MMR) proteins, BRAF V600E, and PD-L1) in a large prospective cohort of 109 tumors. We found that ER and MMR were not impacted; PR, HER2, and BRAF V600E were minimally affected; and PD-L1 regardless of the antibody clone was strongly influenced by a combination of tissue processing procedures and intratumoral heterogeneity. Our findings suggest that validation of pre-analytical parameters, such as tissue processing, is important for certain class II biomarkers, in particular PD-L1 IHC.

Indexed as

ImmunohistochemistryTissue PreservationB7-H1 AntigenBiomarkers, TumorBiopsyDNA Mismatch RepairDNA Repair EnzymesErb-b2 Receptor Tyrosine KinasesHumansNeoplasmsPredictive Value of TestsProspective StudiesProto-Oncogene Proteins B-rafReceptors, EstrogenReceptors, ProgesteroneReproducibility of ResultsB7-H1 AntigenBiomarkers, TumorBRAF protein, humanCD274 protein, humanDNA Repair EnzymesERBB2 protein, humanErb-b2 Receptor Tyrosine KinasesProto-Oncogene Proteins B-rafReceptors, EstrogenReceptors, ProgesteroneClass II biomarkersERImmunohistochemistryPD-L1Pre-analytical

Identifiers

PMID33175216
OpenAlexW3098164123

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.